Longevity Industry: Hype vs. Evidence-Based Strategy
An executive analysis of the longevity market, distinguishing between high-impact biological interventions and low-value wellness trends. The discussion highlights the economic inefficiencies of US healthcare, the rise of GLP-1s, and the critical role of social connection in health outcomes.